Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study

Brausi, Maurizio; Campo, B.; Pizzocaro, Giorgio; Rigatti, Patrìzio; Parma, Antonio; Mazza, G.; Vicini, A.; Stephen, Robert L.

doi:10.1016/s0090-4295(97)00625-0

Cited by 63 publications

(33 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This means that the transport of MMC can be enhanced from 6 to 9 times compared to passive diffusion. The EMDA procedure has already been preliminarily tested for treating various bladder disorders including the prophylaxis of STCCB after TUR [10]or STCCB ablation [28]. According to our administration schedule, both TC and EMDA appeared to be feasible and safe on an outpatient basis.…”

Section: Discussionmentioning

confidence: 99%

Thermo–Chemotherapy and Electromotive Drug Administration of Mitomycin C in Superficial Bladder Cancer Eradication

Colombo¹,

Brausi²,

Pozzo³

et al. 2001

European Urology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Thermo–Chemotherapy and Electromotive Drug Administration of Mitomycin C in Superficial Bladder Cancer Eradication

Colombo¹,

Brausi²,

Pozzo³

et al. 2001

European Urology

Self Cite

View full text Add to dashboard Cite

“…5 However, a pilot study 6 of residual tumour in the bladder after complete transurethral resection in patients with intermediate-risk superficial bladder cancer reported that electromotive mitomycin was no better than passive-diffusion mitomycin (complete response 41·0% vs 41·6%). However, patients who responded to electromotive mitomycin had lower recurrence and higher disease-free interval than did patients who responded to passive-diffusion mitomycin.…”

Section: Sequential Bcg and Electromotive Mitomycin Versus Bcg Alone mentioning

confidence: 99%

“…However, patients who responded to electromotive mitomycin had lower recurrence and higher disease-free interval than did patients who responded to passive-diffusion mitomycin. 6 Furthermore, electromotive mitomycin increases drug delivery by 4-7 times over that of passive transport. 7 A randomised trial 8 of 108 patients with multifocal carcinoma in situ (98 of whom had stage T1 tumours removed by transurethral resection) suggested that BCG and electromotive mitomycin were effective treatment for bladder carcinoma in situ, and that when used alone both agents seemed more effective than did passive-diffusion mitomycin.…”

Section: Sequential Bcg and Electromotive Mitomycin Versus Bcg Alone mentioning

confidence: 99%

Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

Stasi¹,

Giannantoni²,

Giurioli³

et al. 2006

The Lancet Oncology

245

179

View full text Add to dashboard Cite

SummaryBackground The rationale for combining anticancer drugs has not been applied consistently to use of intravesical agents for treatment of superficial bladder cancer, for which immunotherapeutic BCG and chemotherapeutic mitomycin seem to be a potentially effective combination. We aimed to do a prospective, randomised comparison of BCG alone with that of sequential BCG and electromotive mitomycin in patients with stage pT1 bladder cancer.Methods After transurethral resection and multiple biopsies, 212 patients with stage pT1 bladder cancer were randomly assigned to: 81 mg BCG infused over 120 min once a week for 6 weeks (n=105); or to 81 mg BCG infused over 120 min once a week for 2 weeks, followed by 40 mg electromotive mitomycin (intravesical electric current 20 mA for 30 min) once a week as one cycle for three cycles (n=107). Complete responders underwent maintenance treatment: those assigned BCG alone had one infusion of 81 mg BCG once a month for 10 months, and those assigned BCG and mitomycin had 40 mg electromotive mitomycin once a month for 2 months, followed by 81 mg BCG once a month as one cycle for three cycles. The primary endpoint was disease-free interval; secondary endpoints were time to progression; overall survival; and disease-specific survival. Analyses were done by intention to treat. This trial has been submitted for registration at the US National Cancer Institute website http://clinicaltrials.gov. Findings

show abstract

“…In a phase II study Brausi et al [21], treated 13 patients with multifocal Ta-T1/grade 1-2 bladder tumors with 8 weekly MMC 40 mg instillations (instillation time 120 min) and 15 patients with 8 weekly sessions of intravesical EMDA of MMC 40 mg (20 min with an electric current of 15 mA). Before treatment, all bladder tumours except for one marker lesion were resected.…”

Section: Efficacy Of Intravesical Emda/mmcmentioning

confidence: 99%

Updates in intravesical electromotive drug administration® of mitomycin-C for non-muscle invasive bladder cancer

Stasi

Riedl²

2009

World J Urol

View full text Add to dashboard Cite

Electromotive drug administration Ò (EMDA) increases the local drug efficacy by controlling and enhancing transmembranous transport into tissue. EMDA of intravesical mitomycin-C (MMC) has been used for treatment of non-muscle invasive bladder cancer (NMIBC) for about a decade on the basis of laboratory studies that demonstrated an enhanced administration rate of MMC into all bladder wall layers after EMDA compared to standard instillation/passive diffusion (PD). Higher MMC concentrations might have a clinical impact since EMDA was associated with lower recurrence rates than PD in randomized studies. Further data suggest that EMDA/ MMC is at least equivalent to BCG in treatment of highrisk bladder tumours. In addition, BCG combined with EMDA/MMC as well as preoperative EMDA/MMC are new therapeutic strategies with promising preliminary results in terms of higher remission rates and longer remission times. In summary, these findings suggest that EMDA for MMC delivery in the bladder could be a major therapeutic breakthrough in the treatment of NMIBC.

show abstract

Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study

Cited by 63 publications

References 9 publications

Thermo–Chemotherapy and Electromotive Drug Administration of Mitomycin C in Superficial Bladder Cancer Eradication

Thermo–Chemotherapy and Electromotive Drug Administration of Mitomycin C in Superficial Bladder Cancer Eradication

Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

Updates in intravesical electromotive drug administration® of mitomycin-C for non-muscle invasive bladder cancer

Contact Info

Product

Resources

About

Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study

Cited by 63 publications

References 9 publications

Thermo&ndash;Chemotherapy and Electromotive Drug Administration of Mitomycin C in Superficial Bladder Cancer Eradication

Thermo&ndash;Chemotherapy and Electromotive Drug Administration of Mitomycin C in Superficial Bladder Cancer Eradication

Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

Updates in intravesical electromotive drug administration® of mitomycin-C for non-muscle invasive bladder cancer

Contact Info

Product

Resources

About

Thermo–Chemotherapy and Electromotive Drug Administration of Mitomycin C in Superficial Bladder Cancer Eradication

Thermo–Chemotherapy and Electromotive Drug Administration of Mitomycin C in Superficial Bladder Cancer Eradication